Dutasteride has been extensively studied in randomized controlled trials for both BPH and androgenetic alopecia. This section provides plain-language summaries of the most important clinical studies, including the landmark REDUCE trial, the pivotal Olsen Phase II trial for hair loss, and the most recent 2025 Phase II topical dutasteride trial. Each summary includes study design, key results, and practical implications. Dutasteride is FDA-approved for benign prostatic hyperplasia only, so every hair loss use described in this section is off-label in the United States.
Key Hair Loss Studies
- 2025 Phase II Topical Dutasteride Trial (PMC12405733): placebo and active controlled trial of topical dutasteride against oral finasteride
- IJDVL Dutasteride vs Finasteride RCT: head-to-head comparison at standard clinical doses
- Karger 2024 Dermatology Review: updated review of dutasteride for AGA
- Low-Dose 0.2 mg Study: Phase III trial of 0.2 mg against 0.5 mg and placebo
- Twice-Weekly Dosing Protocol: intermittent dosing regimens tested against daily finasteride
- Dutasteride Monotherapy Evidence: randomized monotherapy hair count results
- Mesotherapy (Injectable) Studies: scalp injection of dutasteride
- Combination Therapy Research: multi-drug approaches
- Dutasteride in Postmenopausal Women: female hair loss evidence
Key BPH / Prostate Studies
- REDUCE Trial: largest dutasteride prostate cancer prevention trial
- Long-Term Safety Data: multi-year safety analysis
- 5ARI Class Review: comparison of the 5-alpha reductase inhibitors
What is dutasteride · How it works · Side effects · Full source list